GCL
PSTX

Glazer Capital LLC’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Glazer Capital LLC’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-878
Closed -$4K – 232
2024
Q4 		$4K Buy
+878
New +$4.58K ﹤0.01% 141

Other funds holding PSTX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glazer Capital LLC's PSTX Position: Q1 2025 in Review

Glazer Capital LLC sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 521,113 shares — an estimated $5M sold.

Glazer Capital LLC first reported a position in PSTX in Q4 2024 and held it in 1 quarter. The position peaked at $5M in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

  • Glazer Capital LLC reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Glazer Capital LLC sold 521,113 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $5M.
  • Glazer Capital LLC first reported a position in Poseida Therapeutics, Inc. Common Stock in Q4 2024 and held it in 1 quarter.
  • Glazer Capital LLC's Poseida Therapeutics, Inc. Common Stock position peaked at $5M in Q4 2024.
  • 1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Glazer Capital LLC's 13F filing for Q1 2025, filed 15 May 2025.